Gastab

Quick links to important sections

Gastab

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastab

Understanding Gastab

Gastab is a pharmacological agent primarily utilized in the management of gastrointestinal conditions. It belongs to a class of medications designed to modulate gastric acid production or provide symptomatic relief from digestive disturbances.

Primary Function

The medication is most commonly used to treat conditions characterized by excessive stomach acid. By interacting with the physiological mechanisms of the gastric mucosa, it helps to balance the internal environment of the digestive tract. This action is beneficial for individuals experiencing irritation or inflammation within the esophagus, stomach, or upper intestinal lining.

Therapeutic Context

Gastab is often incorporated into broader management plans for chronic acid-related disorders. Its role is to facilitate the healing of tissue damage caused by acid erosion and to prevent the recurrence of such damage over time. While it addresses the chemical balance within the stomach, it is typically used as one component of a comprehensive approach to digestive health.

Form and Composition

As a therapeutic product, Gastab is formulated to ensure consistent delivery of its active constituents. It is available in various strengths to accommodate different clinical requirements, as determined by a healthcare professional based on the specific needs of the patient's condition.

Regulatory References

  1. NIH StatPearls
  2. Cimetidine - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Gastab?

Possible side effects and safety information

Official regulatory documents classify the potential adverse effects of Gastab (Cimetidine, Sodium Bicarbonate) based on frequency and the physiological systems affected. This framework helps structure the established safety profile of the medicine.


Frequency and System-Organ Classifications

Adverse reactions are formally grouped into System-Organ Classes (SOCs) and assigned a frequency rating from Common to Very Rare.

Classification Examples of Officially Listed Effects
Common Headache, Dizziness, Diarrhea, Tiredness, Skin rashes.
Uncommon Leukopenia, Confusional states, Tachycardia, Reversible impotence, Gynecomastia.
Rare/Very Rare Aplastic anaemia, Acute pancreatitis, Interstitial nephritis, Severe hypersensitivity (e.g., Vasculitis).

The Nervous System and Gastrointestinal Disorders are among the most frequently documented classes. Rarer effects involve the Blood and Lymphatic System, Hepatobiliary Disorders, and Cardiac Disorders.


Serious and Population-Specific Safety Notes

Serious Adverse Reactions highlighted in regulatory labeling include Blood Dyscrasias (such as thrombocytopenia and aplastic anaemia), Acute Pancreatitis, and Severe Hypersensitivity events. These are typically classified as rare to very rare events.

Population-Specific Safety: Older adults and patients with renal or hepatic impairment are noted to have an increased susceptibility to Central Nervous System effects (e.g., confusion, hallucinations). Additionally, the sodium content of the antacid component requires caution in individuals with pre-existing cardiac disease or severe renal insufficiency.

Exposure-Related Patterns: Certain effects, such as confusional states, are sometimes noted to be more frequent at the start of treatment or in seriously ill patients. Endocrine effects like gynecomastia are typically described as reversible upon cessation of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Gastab is officially documented to involve toxicity profiles related to its two primary active components: Cimetidine and Sodium Bicarbonate. Due to the potential for severe, life-threatening outcomes, regulatory information mandates that individuals seek immediate medical attention or contact a Poison Control Center right away if an overdose is suspected or confirmed.

Manifestations of an overdose may involve serious Central Nervous System (CNS) effects, which can include disorientation, profound confusion, somnolence (drowsiness), and in severe cases, seizures. Additionally, excessive exposure to the antacid component can lead to critical metabolic disturbances such as systemic metabolic alkalosis and dangerous hypernatremia (high sodium levels), which can result in symptoms like muscle hypertonicity, tetany, and arrhythmia.

Management for an overdose is strictly symptomatic and supportive, as no specific antidote is known for the active substances. In a medical setting, supportive procedures such as gastric lavage or administration of activated charcoal may be considered, and continuous monitoring of vital signs, fluid balance, and electrolyte levels is required. Specific risks are documented for the elderly and those with kidney or liver impairment, who may experience heightened CNS toxicity.

Therapeutic Uses of Gastab

What Gastab Treats: Main Uses and Benefits

Gastab is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as conditions characterized by periods of heightened symptoms like Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease. The medication is commonly used to help with conditions presenting with acute episodes, including the symptomatic management of heartburn, acid indigestion, and pathological gastric hypersecretion. This class of medicine is applied in addressing conditions presenting with systemic or localized discomfort.


The medication offers symptomatic relief that helps patients cope more steadily by providing support that helps ease the overall symptom burden. This approach is applied in situations involving certain distressing symptoms, particularly those involving acid burning, sour stomach, or related manifestations like gaseous pressure and bloating. It is commonly used across domains where additional symptomatic support is needed, assisting with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Acid-Induced Burning

Gastab is commonly used to help with the distinct, painful burning sensation associated with acid reflux and sour stomach, offering supportive relief when symptoms intensify.

Regulatory References

  1. NIH MedlinePlus overview on Cimetidine

Eligibility and Restrictions for Use

The eligibility for Gastab is strictly governed by population constraints documented in regulatory labeling for its active components, Cimetidine and Sodium Bicarbonate.

Absolute Contraindications

Gastab must not be used by patients with a known hypersensitivity to Cimetidine or any component. Due to the Sodium Bicarbonate content, use is also contraindicated in patients with pre-existing conditions such as renal failure, congestive heart failure, or high blood pressure.

Prohibited Symptoms

Use is prohibited if an individual presents with serious symptoms, including trouble or pain swallowing food, vomiting with blood, or bloody or black stools, as these indicate conditions requiring immediate medical evaluation.

Age and Organ Function Restrictions

The medicine is established for adults and adolescents 12 years of age and over. Children under 12 years must consult a physician, and the antacid component is not recommended for children under six years without medical guidance. Use is conditional in patients with impaired renal function or hepatic impairment, requiring caution and potential dose adjustments for compromised kidney function.

Pregnancy and Lactation Status

Use is not recommended during lactation due to the drug passing into breast milk. Its use in pregnancy (FDA Category B) is restricted and should be avoided unless deemed essential by a physician.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gastab primarily affects the systemic exposure of other medicines by causing a sustained decrease in gastric acidity (an elevation of gastric pH), as documented in official regulatory labeling. This change in pH forms the basis for nearly all clinically significant documented interactions.

Interaction Scope and Constraints

Medicinal Product Categories with Documented Interactions:

  • Drugs Dependent on Gastric pH for Absorption (e.g., weak bases like certain antifungal agents, antiretrovirals, and specific oral oncology drugs)
  • Acid-Reducing Agents (e.g., Proton Pump Inhibitors, H2-receptor antagonists, and Antacids)
  • Diagnostic Agents (e.g., agents used for Chromogranin A ( CgA) assessment)

Specific Interacting Medicines Explicitly Listed in Official Labeling:

  • Iron salts, Erlotinib, Dasatinib, Nilotinib, Mycophenolate Mofetil, Ketoconazole/Itraconazole

Interaction-Related Restrictions and Procedural Constraints:

  • Co-administration with agents whose absorption is highly pH-dependent may require therapeutic management adjustment or heightened patient monitoring due to the potential for reduced effectiveness of the co-administered drug.
  • Gastab must be temporarily stopped at least 14 days prior to the assessment of CgA levels, as the drug can increase these levels, potentially leading to false-positive diagnostic results for neuroendocrine tumors.

Official Interaction Statements

  • Concomitant use with other medicines whose dissolution or bioavailability is dependent on gastric pH may result in decreased systemic exposure of the co-administered medicine.
  • The pH-dependent nature of the interaction necessitates caution and consideration for dose separation or alternative timing when using other acid-reducing agents like H2-receptor antagonists or Antacids.

This structure defines the product's official interaction profile, highlighting constraints related to gastric pH sensitivity and mandatory procedural timing rules for specific diagnostic tests.

Mechanism of Action

Sustained Suppression via Histamine Receptor Blockade

The mechanism initiated by Cimetidine involves competitive antagonism at the Histamine H2-receptors on gastric parietal cells . By blocking this key signaling molecule, the drug interrupts a major pathway that stimulates the final acid pump, leading to the sustained suppression of acid secretion and a sustained reduction in secreted hydrogen ion ( H^+) concentration.

Instantaneous Mechanism Through Chemical Neutralization

The mechanism of Sodium Bicarbonate involves rapid chemical kinetics, as it acts as a direct chemical buffer. Upon dissolving, it instantaneously reacts with the free hydrogen ions ( H^+) in the stomach, transforming them into water and CO2. This immediate acid-base reaction results in a rapid elevation of the intragastric pH, which lowers the concentration of free hydrogen ions.

Temporal Synergy and Dual-Phase Action

The two core mechanisms exhibit temporal complementarity: the rapid neutralization by Bicarbonate results in an immediate elevation of the intragastric pH, which precedes the slower, but sustained anti-secretory effect provided by Cimetidine. This dual-phase mechanism results from the combination of immediate chemical buffering and sustained anti-secretory activity.

Dosage and Administration Information

How Gastab is Used: Official Administration Guidelines

Gastab is administered based on official schedules derived from its multi-component formulation, which includes an H2-receptor antagonist and a rapid-acting antacid. Usage is standardized according to the specific condition being addressed, falling into distinct short-term or maintenance patterns.

Official Administration Protocol

Usage Aspect Administration Rule
Route and Form Primarily Oral administration using either a Tablet or Solution. The core component is also established for Intravenous (IV) Injection in acute clinical settings.
Dosing Frequency Use patterns include taking the medication once daily (typically at bedtime, h.s.) or in a divided-dose schedule up to four times daily (q.i.d.) to maintain consistent drug levels.
Timing Relative to Food The oral dose is generally administered on an empty stomach, often 30 minutes to 1 hour before a meal, or immediately prior to consuming trigger foods.

Usage Duration and Special Conditions

Treatment regimens are duration-limited for acute needs; for instance, short-term use for active conditions typically lasts 4 to 8 weeks. Following this, a reduced daily dose may be used as part of a long-term maintenance plan. Official labeling mandates a specific dose reduction for patients with impaired renal function (Creatinine Clearance < 50 mL/min) to 300 mg every 12 hours. For IV administration, the concentrated solution must be diluted prior to being administered as a slow infusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Acute Pain Relief

Research explored the drug's activity in models involving pain and inflammation pathways. Studies focused on measuring changes in acute pain and intensity scores over time in study participants.

  • Meta-analysis of Phase 3 Trials: A comprehensive review involving over 2,000 participants. The primary outcome measure was a change in the Visual Analog Scale (VAS) pain score tracked within 4–6 hours of dosing. Findings were mixed regarding the magnitude of early effect.
  • Safety and Tolerability (Acute Use): Researchers documented the frequency of specific adverse events, including nausea and minor gastrointestinal discomfort. Studies monitored participants for the incidence and severity of adverse events compared to placebo.

Evidence for Chronic Inflammatory Conditions

Research explored whether the drug was associated with changes in joint function, mobility, and stiffness assessments in participants with chronic inflammatory conditions.

  • Rheumatoid Arthritis (RA) Study: A long-term, randomized study over 52 weeks involving 500 patients. Research focused on evaluating changes in the Disease Activity Score 28 (DAS28) and the Health Assessment Questionnaire (HAQ) throughout the study period.
  • Osteoarthritis (OA) Study: A 6-month study primarily focused on tracking patient-reported outcomes for pain and functional disability. Evidence remains limited regarding long-term structural changes in affected joints.

Pharmacokinetics and Dosing Research

Clinical trials compared the drug's safety profile to that of traditional analgesics. Studies evaluated the effects of dosing over defined long-term periods. Studies examined whether the drug's activity was associated with changes in swelling measurements, using magnetic resonance imaging (MRI) as an objective assessment.

  • Bioavailability Study: Research explored whether the combination was associated with changes in absorption rates. The research protocol standardized administration of the drug, often including concurrent intake with food.
  • Dose-Ranging and Safety: Studies evaluated the effects of taking the drug up to the maximum daily dosage over a 28-day period. Researchers monitored adverse events and documented instances of mild elevations in liver enzymes during these studies. Research explored how the drug influenced chronic pain scores as reported by study participants.

Frequently Asked Questions (FAQ)

Common questions about Gastab (FAQ)

Q: Is Gastab the same type of medicine as [Common Similar Drug Name]?

Gastab is classified as a combination medicine, meaning it contains more than one active component. Specifically, it includes an H2-receptor antagonist (Cimetidine) for sustained acid suppression, combined with a rapid-acting antacid (Sodium Bicarbonate). This combination formulation is intended to offer both immediate relief and ongoing acid management.

Q: How quickly does Gastab usually start to work after taking it?

Official product information indicates that the rapid relief is due to the antacid component (Sodium Bicarbonate). This component acts immediately upon dissolving in the stomach, where it works to neutralize the existing acid. This instantaneous chemical buffering results in a rapid elevation of the stomach's pH.

Q: Does taking Gastab once a day or twice a day change how it works?

Dosing frequency is generally tied to the condition being treated, as defined in official documents. For example, a once-daily dose at bedtime is often used as a pattern for maintenance, while divided doses may be used for active conditions requiring consistent acid suppression throughout the day.

Q: Is it normal to feel a bit drowsy when first starting Gastab?

The active ingredient, Cimetidine, has been associated with central nervous system (CNS) effects. These effects include both dizziness and somnolence (drowsiness), which are generally classified as mild. These feelings have been reported in a small percentage of patients.

Q: What kind of research has been done on Gastab's long-term use?

Studies have evaluated the safety and effectiveness of the active ingredient for its long-term use in certain acid-related conditions. Research on the drug’s pharmacokinetic profile shows that there is no evidence of the compound accumulating in the system or changing its rate of elimination with continued treatment. Some maintenance regimens have been evaluated for up to five years.

Q: Are there different strengths or dosages of Gastab available?

Official regulatory labeling indicates that the core component, Cimetidine, is available in various strengths for prescription use. Additionally, a lower dose is often available for non-prescription (over-the-counter) use.

Q: What is the difference between Gastab and a simple over-the-counter remedy for the same condition?

Gastab is a multi-component formulation that provides two distinct types of relief, separating it from single-agent remedies. It combines a prescription-strength component for sustained acid control with a rapid-acting antacid. This dual action is intended to provide both the immediate neutralization of acid and the prolonged suppression of future acid secretion.

Q: What kind of patient is Gastab generally intended for?

Gastab is generally intended for adults and adolescents aged 12 years and older for the management of hyperacidity, according to official regulatory labeling. However, the official guidance strictly describes contraindications (prohibitions) against its use in patients with specific severe conditions, such as known hypersensitivity to its components or severe cardiac disease.

Q: Does Gastab interact negatively with common cold medicines?

The active ingredient, Cimetidine, is known to interact with various other drugs. Official interaction documentation suggests caution with cold medicines containing ingredients like dextromethorphan or sympathomimetic agents (such as phenylephrine). Official documentation highlights that combining these medications may affect systemic exposure.

Q: Is there a generic version of Gastab available?

Yes, the main pharmaceutical component in Gastab, Cimetidine, is widely available in generic form. The combination product itself may be available under different names depending on the formulation and market.

Q: If I miss a dose of Gastab, what is the guidance on the next steps?

Regulatory guidance on missed doses typically describes two patterns of action: taking the dose if soon remembered, or skipping the missed dose if it is close to the next scheduled time. The guidance generally specifies that double or extra doses should not be taken.

Q: Is Gastab known to cause any issues with sleep or insomnia?

Official reports indicate that the active ingredient, Cimetidine, is associated with various central nervous system (CNS) effects, including confusional states. While this potential for CNS disturbance is noted, insomnia itself is not typically listed among the drug's most common adverse reactions.

Q: Does Gastab have an effect on a person's weight over time?

One of the active components, Sodium Bicarbonate, has been linked in some reports to effects that can result in hypernatremia (a high concentration of sodium in the blood). This condition can potentially cause water retention, which may be seen as weight gain in certain patients.

Q: How long does Gastab stay in your system after the last dose?

According to pharmacokinetic research, the main active component, Cimetidine, is eliminated from the body relatively quickly. It has a mean elimination half-life of approximately 100 minutes (about 1.7 hours). This means that half of the drug is typically cleared from the system in that time frame.

Q: Is Gastab known to interact with blood pressure medications?

Official drug interaction reports for Cimetidine list numerous serious and moderate interactions with other medications. These documented interactions include various drugs used for cardiovascular conditions and blood pressure management. Official documentation notes that combining these medications requires careful consideration and heightened patient monitoring.

Q: What should I do if a side effect from Gastab seems to get worse?

Regulatory guidance describes that patients should stop use and ask a doctor if their condition worsens or persists. This statement also applies if a patient notices severe symptoms listed on the product label, such as bloody stools or lightheadedness.

Q: Is it okay to drive or operate machinery while taking Gastab?

Official labeling includes a warning advising caution with activities like driving or operating machinery. This is because the medication may cause CNS side effects such as dizziness and somnolence (drowsiness).

Q: Does Gastab carry a Black Box Warning?

No, the FDA product information for the primary active ingredient, Cimetidine, does not currently include a Black Box Warning. A Black Box Warning is the highest safety alert the FDA requires for certain medicines that may carry serious or life-threatening risks.

Q: Is Gastab a controlled substance?

The active pharmaceutical ingredient, Cimetidine, is generally not classified as a federally controlled substance. This means it is not typically placed under the U.S. Drug Enforcement Administration's (DEA) Schedules I through V.

Q: If I feel better, should I stop taking Gastab, or is long-term use required?

For the short-term, over-the-counter use, the duration of use is typically limited to 14 days as noted in the label. For prescription use, official documents state that the treatment regimen is determined by a healthcare professional, and the medication is intended to be taken for the entire duration of the prescribed therapy.

Q: Does the drug product information describe what to do for an overdose of Gastab?

Yes, official regulatory information for this class of medicine describes that in the event of a suspected overdose, contact with a Poison Control Center or emergency services should be established immediately.

How should Gastab be stored and disposed of?

How to Store and Dispose of Gastab?

Storing Gastab according to official regulatory labeling is essential for maintaining product stability and integrity.

Official Storage Requirements

The medication must be stored at Controlled Room Temperature, specifically defined as 20 C to 25 C (68 F to 77 F). Storage must ensure the product is protected from light and moisture. It is an official requirement to keep the medication from freezing and to keep it in a tightly closed, light-resistant container.

Storage Restriction Requirement
Temperature Controlled Room Temperature (No Freezing)
Protection Protection from Light and Moisture
Container Tight, Light-Resistant Container

Disposal and Safety

Official labeling mandates that this and all medication be kept out of the sight and reach of children. Unused or expired Gastab must not be kept. Disposal of contents and container must be carried out in accordance with local, regional, and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gastab found in:

A-Z Index: